• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld, Analysis and data insight

BioWorld, Analysis and data insight
BioWorld, Analysis and data insight RSS Feed RSS

Health professional touching screen, digital/medical icons
AI partnerships ‘move the industry forward’

Trial recruitment, retention improved but drop-outs persist in late studies

Feb. 11, 2020
By Marie Powers
Multiple tactics employed by the biopharma industry to improve the recruitment and retention of participants in clinical trials seem to be paying off. More than three of four (77%) studies now fully enroll on or ahead of schedule, according to researchers at the Tufts Center for the Study of Drug Development (CSDD), reporting in the January/February Tufts CSDD Impact Report on global recruitment performance benchmarks.
Read More

Week in review for Feb. 3-7, 2020: Investors start to get nervous about sector’s prospects

Feb. 10, 2020
By Peter Winter
A quick look back at top stories.
Read More

Money raised by biopharma: 2020 vs. 2019

Feb. 7, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-Feb. 6, 2020

Feb. 7, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Test tube, dropper

Phase I clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase I trials in January 2020, including: Adaptimmune, Agenus, Astellas, Autolus, Aveo Oncology, Bellicum, Biotheryx, Briacell, Cellectis, Celyad, Cstone, Cytodyn, Exelixis, Faron, Forma, Geneos, Glycomimetics, Ikena, Immunitybio, Inhibrx, Invectys, Isofol Medical, Leap, Lipomedix, Medigene, Midatech, Miragen, Nantkwest, NEC, Oric, Oxford, Pharmajet, Pharmamar, Rafael, SQZ, Sun, Syros, Targovax, Tmunity, Transgene, Trovagene, Unum.
Read More

Phase II clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase II trials in January 2020, including: Acceleron, Akcea, Bergenbio, Cytokinetics, Daiichi Sankyo, Delmar, Durect, Galapagos, Hutchison China, I-Mab, Immutep, Iovance, Kalvista, Khondrion, Orphazyme, Pellepharm, Tenax, Tolero, Tyme, VBL, Xeris, Zai Lab.
Read More

Phase III clinical trials: January 2020

Feb. 7, 2020
Therapeutic area data reported by biopharma companies on phase III trials in January 2020, including: Abbvie, Astrazeneca, Beigene, Biofrontera, Eli Lilly, EMD Serono, Erytech, Evolus, Incyte, Innovent, Isofol Medical, Kala, Kyowa Kirin, Lipidor, Merck, Nucana, Orion, Rafael, Roche, Sellas Life Sciences, VBL, Verastem.
Read More
Arrows pointing upward

Biggest gainers and losers for the week of Feb. 3-7, 2020

Feb. 7, 2020
The top 10 biopharma stock gainers and losers for the week.
Read More

Investors looking for repeat performance from drug developers

Feb. 4, 2020
By Peter Winter
Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear. The price-weighted index returned 40% in value thanks to a steady flow of positive regulatory and clinical trial results from the companies throughout the year. However, investors may be less impressed with the start they have made this year, with the index dipping 8.4% in January.
Read More
Dollar sign thermometer
Great expectations

Lukewarm start to year weighs heavily on sector’s performance

Feb. 3, 2020
By Peter Winter
Biotech investors had every reason to feel bullish heading into the new decade. The sector had turned around in 2019 and was riding a wave of a very strong fourth-quarter performance, with the BioWorld Biopharmaceutical Index closing up 14% for the year after being underwater from April through to September. Unfortunately, those great expectations were quickly erased during J.P. Morgan Healthcare conference week (Jan. 10 – Jan. 17), which turned out to be a very low-key affair absent of any blockbuster M&A revelations. As a result, confidence has now given way to concerns about the prospects for biopharmaceutical companies going forward, particularly as unfavorable political rhetoric on drug pricing will certainly be dialed up during this election year.
Read More
Previous 1 2 … 181 182 183 184 185 186 187 188 189 … 203 204 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 23, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe